BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, March 29, 2024
Home
»
Newsletters
» BioWorld
BioWorld
Sep. 22, 2004
View Archived Issues
Xenon, Novartis Enter $157M Deal For Obesity Compounds
In a deal that could bring Xenon Pharmaceuticals Inc. $157 million in pre-commercial payments, Novartis Pharma AG agreed to research, develop and commercialize compounds from Xenon's SCD1 drug development program. (BioWorld Today)
Read More
'Two Pathways' Now Mapped For Anidulafungin's Approval
Read More
Multitasking Histone Molecule SAHA Affects Kidney Disease
Read More
Coley's Anti-Terrorism TLRs Get Another $16.9M Contract
Read More
Other News To Note
Read More